Ankylosing spondylitis (AS) is a kind of arthritis that mostly affects the spine, resulting in chronic inflammation of the spine, shoulder, and hip joints. As spondylitis progresses between the rib and spine joints, it gradually inhibits chest movement, making it harder to breathe properly. Ankylosing spondylitis, in its advanced state, produces vertebral fractures. Ankylosing spondylitis symptoms include pain and swelling in a finger or toe, tenderness at the base of the pelvis, chest pain, and fatigue. It typically arises between the ages of 17 and 45, usually during late adolescence. There is currently no cure for ankylosing spondylitis, although several therapies and drugs are available to assist lessens symptoms and manages pain. Frequent back exercise and fitness activities can also help manage the symptoms of ankylosing spondylitis. 

Market Drivers: The market for ankylosing spondylitis (AS) is quickly rising as treatment options increase. The most important area of change in AS treatment is with biologic medicines, notably TNFi and interleukin inhibitors. The primary benefits of biologics are focused interventions against disease pathways that lead to inflammation and disease development, resulting in better patient outcomes. Furthermore, advancements in ankylosing spondylitis therapy are expected to further drive market growth. Improved diagnostic procedures have resulted in earlier and more accurate detection, allowing for prompt intervention and improved patient outcomes. Addressing issues such as treatment costs and access to healthcare is predicted to be critical for continued market growth.

Challenges: The ankylosing spondylitis treatment market is expected to be hampered during the forecast period due to a shortage of competent surgeons which projects an inability to obtain effective medications for treatment, and the high cost of treatment. TNF inhibitors and IL 17 inhibitors are frequently priced at a premium, rendering them unavailable to many patients, particularly in low and middle income nations. This financial burden can reduce adherence to treatment regimens, resulting in poor patient results. Furthermore, delayed identification due to non specific early symptoms of AS frequently results in disease development before proper therapy can begin, lowering the efficacy of existing drugs.

Market Trends: There are some of the leading pharmaceutical companies who are spending extensively in biologics, notably TNF and IL 17 inhibitors, which have demonstrated great success in treating ankylosing spondylitis symptoms. Biosimilar are also gaining popularity, providing less expensive alternatives to biologic treatments. Companies are concentrating on creating targeted medicines based on genetic and molecular profiling in order to improve treatment efficacy and minimize negative effects. Pharmaceutical companies are forming mergers, acquisitions, and strategic partnerships to improve their research and development (R&D) skills and grow their product pipelines. Research into stem cell treatment and regenerative medicine is gaining traction as corporations look for new ways to manage long-term diseases and perhaps modify them.

AbbiVie, Inc, Amgen, Inc, Eli Lilly and Company, Izana Biosciences, Johnson and Johnson Services, Inc, Merck and Co., Inc, Novartis AG, Pfizer, Inc, UCB, Inc, and Zydus Lifescience Ltd.

By Drug Class: Based on the Drug Class, Global Ankylosing Spondylitis Market is segmented as; Non Steroidal Anti-Inflammatory Drug (NSAID), TNF Inhibitors.

By Distribution Channel: Based on the Distribution Channel, Global Ankylosing Spondylitis Market is segmented as; Hospital Pharmacy, Retail Pharmacy.

By Region: This research also includes data for North America, Latin America, Asia-Pacific, Europe, Middle East & Africa.

This study also encompasses various drivers and restraining factors of this market for the forecast period. Various growth opportunities are also discussed in the report.